Cross-Cultural Adaptation and Psychometric Properties of the Swahili Version of the European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR45 among Breast Cancer Patients in Tanzania.
breast cancer
psychometric properties
quality of life
reliability
validation
Journal
Healthcare (Basel, Switzerland)
ISSN: 2227-9032
Titre abrégé: Healthcare (Basel)
Pays: Switzerland
ID NLM: 101666525
Informations de publication
Date de publication:
05 Sep 2023
05 Sep 2023
Historique:
received:
30
07
2023
revised:
28
08
2023
accepted:
31
08
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Breast cancer is the most frequent cancer in women in Africa and contributes to premature death and poor quality of life. This study aimed to determine the validity, reliability, and psychometric properties of the Swahili version of EORTC QLQ-BR45 among women with breast cancer in Tanzania. A cross-sectional study design with non-probability convenience sampling was employed. Data were collected in two tertiary hospitals and one national cancer institute; 414 participants completed the EORTC-QLQ-C-30 and EORTC-QLQ-BR45. The reliability of QLQ-BR45 was measured using Cronbach's alpha and McDonald's Omega coefficients. The factor structure of EORTC QLQ-BR45 was assessed using confirmatory factor analysis. The internal consistencies for the five dimensions were all above 0.7 indicating satisfaction, except for systemic therapy side effects with a marginal value of 0.594 and significant correlations between the dimensions of QLQ-C30 and BR45. The final model fit well to the data, with the comparative fit index = 0.953, Tucker-Lewis index = 0.947, root mean square error of approximation = 0.041 (90% CI: 0.035, 0.046), and standardized root mean square residual = 0.072. In conclusion, the QLQ BR45 Swahili version displayed good reliability, validity, and psychometric properties and can be used in Swahili-speaking Sub-Saharan countries.
Identifiants
pubmed: 37761665
pii: healthcare11182467
doi: 10.3390/healthcare11182467
pmc: PMC10530899
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Qual Life Res. 2014 Dec;23(10):2883-8
pubmed: 24848597
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
SAGE Open Nurs. 2023 Feb 16;9:23779608231157332
pubmed: 36814460
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eval Health Prof. 2021 Dec;44(4):385-394
pubmed: 33054372
Front Oncol. 2022 Aug 02;12:955057
pubmed: 35982958
Psychooncology. 2020 Jul;29(7):1123-1131
pubmed: 32281174
Maturitas. 2016 Dec;94:87-91
pubmed: 27823751
Health Qual Life Outcomes. 2012 Nov 02;10:133
pubmed: 23121718
SAGE Open Nurs. 2023 Jul 10;9:23779608231187241
pubmed: 37441435
Front Public Health. 2023 Feb 28;11:1069422
pubmed: 36926172
PLoS One. 2022 Oct 6;17(10):e0275639
pubmed: 36201503
BMC Health Serv Res. 2022 Feb 12;22(1):189
pubmed: 35151290
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76
pubmed: 8433390
Int J Cancer. 2021 Apr 5;:
pubmed: 33818764
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
J Clin Oncol. 1996 Oct;14(10):2756-68
pubmed: 8874337
East Afr J Public Health. 2011 Mar;8(1):52-7
pubmed: 22066285
BMJ Open. 2023 Apr 13;13(4):e067715
pubmed: 37055211
BMC Cancer. 2019 Jan 17;19(1):82
pubmed: 30654794
Med Care. 2006 Nov;44(11 Suppl 3):S50-9
pubmed: 17060836
BMJ Open. 2016 Nov 22;6(11):e012753
pubmed: 27881528
BMC Public Health. 2020 Jun 15;20(1):930
pubmed: 32539723
PLoS One. 2022 Feb 4;17(2):e0262635
pubmed: 35120148
Lancet Oncol. 2017 Apr;18(4):430
pubmed: 28238599
Lancet Oncol. 2022 Jun;23(6):719-728
pubmed: 35550275
Ann Oncol. 2020 Feb;31(2):283-288
pubmed: 31959345